ING4 and infection: Finally, we tested if supplementing infection media with Avastin (Bevacizumab), a recombinant humanised monoclonal antibody developed against soluble VEGF to prevent receptor binding [61], may increase oncolytic potency of CRAd-IL24 and/or CRAd-ING4 in OvCa cells.